AZACTAM IN PLASTIC CONTAINER Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Azactam In Plastic Container, and what generic alternatives are available?
Azactam In Plastic Container is a drug marketed by Bristol Myers Squibb and is included in one NDA.
The generic ingredient in AZACTAM IN PLASTIC CONTAINER is aztreonam. There are eight drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the aztreonam profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Azactam In Plastic Container
A generic version of AZACTAM IN PLASTIC CONTAINER was approved as aztreonam by FRESENIUS KABI USA on June 18th, 2010.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for AZACTAM IN PLASTIC CONTAINER?
- What are the global sales for AZACTAM IN PLASTIC CONTAINER?
- What is Average Wholesale Price for AZACTAM IN PLASTIC CONTAINER?
Summary for AZACTAM IN PLASTIC CONTAINER
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 4 |
| Clinical Trials: | 2 |
| Patent Applications: | 8,361 |
| DailyMed Link: | AZACTAM IN PLASTIC CONTAINER at DailyMed |
Recent Clinical Trials for AZACTAM IN PLASTIC CONTAINER
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Virginia Commonwealth University | Phase 2 |
| Eastern Virginia Medical School | Phase 2 |
US Patents and Regulatory Information for AZACTAM IN PLASTIC CONTAINER
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | AZACTAM IN PLASTIC CONTAINER | aztreonam | INJECTABLE;INJECTION | 050632-003 | May 24, 1989 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bristol Myers Squibb | AZACTAM IN PLASTIC CONTAINER | aztreonam | INJECTABLE;INJECTION | 050632-002 | May 24, 1989 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bristol Myers Squibb | AZACTAM IN PLASTIC CONTAINER | aztreonam | INJECTABLE;INJECTION | 050632-001 | May 24, 1989 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for AZACTAM IN PLASTIC CONTAINER
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences Ireland UC | Cayston | aztreonam | EMEA/H/C/000996 Cayston is indicated for the suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged 6 years and older.Consideration should be given to official guidance on the appropriate use of antibacterial agents. |
Authorised | no | no | no | 2009-09-21 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
